Abstract： Objective： To observe the clinical effect of modified Huazhuo Jiedu Qingyou prescription combined with routine western medicine for advanced gastric cancer patients with positive helicobacter pylori(Hp). Methods：A total of 93 cases of patients with advanced gastric cancer with positive Hp were selected and divided into the control group and the observation group according to the random number table method，46 and 47 cases in each group respectively. The control group was treated with routine western medicine，and the observation group was additionally treated with modified Huazhuo Jiedu Qingyou prescription based on the treatment of the control group. The changes in Chinese medicine syndrome scores and T lymphocyte subsets including CD3+，CD4+，CD8+ and CD4+/CD8+ in peripheral blood before and after treatment，the recent curative effect， the occurrence of adverse reactions and one- year survival rates after treatment in the two groups were compared. Results：Rank sum test showed that the recent curative effect in the observation group was better than that in the control group(P＜0.05). The χ2 test showed that the clinical disease control rate(DCR) in the observation group was significantly higher than that in the control group(P＜0.05). After treatment， the Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment(P＜0.05)，and the score in the observation group was lower than that in the control group(P＜0.05). The comparison of CD3+，CD4+，CD8+ and CD4+/CD8+ in peripheral blood before and after treatment in the observation group showed no significance in the difference(P＞0.05)；after treatment，the levels of CD3+，CD4+ and CD4+/CD8+ in the control group were significantly lower than those before treatment and those in the observation group(P＜0.05). The incidences of gastrointestinal reactions and bone marrow suppression in the observation group were significantly lower than those in the control group(P＜0.05)；there was no significant difference being found in the comparisons of the incidences of liver and kidney damage， abnormal skin and subcutaneous tissue， and neurotoxicity between the two groups(P＞0.05). After treatment， the one- year survival rate in the observation group was significantly higher than that in the control group(P＜0.05). Conclusion： The therapy of modified Huazhuo Jiedu Qingyou prescription combined with routine western medicine for advanced gastric cancer patients with positive Hp can significantly improve their clinical symptoms， clinical effect and one- year survival rate， and reduce the damage of immune function and adverse reactions.